Home/Pipeline/PTD802

PTD802

Multiple Sclerosis

Phase 1Active

Key Facts

Indication

Multiple Sclerosis

Phase

Phase 1

Status

Active

Company

Pheno Therapeutics

About Pheno Therapeutics

Pheno Therapeutics is a private, clinical-stage UK biotech pioneering a novel approach to neuroprotection by antagonizing the GPR17 receptor on oligodendrocytes. The company's strategy aims to overcome inhibitory signals in diseased brains, promoting remyelination and axonal protection in disorders like multiple sclerosis, Alzheimer's, and ALS. With a recently authorized clinical trial for its lead candidate PTD802 in MS, Pheno is transitioning its platform into human validation, backed by a team of experienced biotech executives and academic key opinion leaders.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Demyelinating Diseases

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Evobrutinib	Merck KGaA	Phase 3	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
REBIF (interferon beta-1a)	EMD Serono	Approved	Active (Lifecycle Management)